<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139580">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944982</url>
  </required_header>
  <id_info>
    <org_study_id>HNJ-NKAES-2012</org_study_id>
    <secondary_id>2012-000054-63</secondary_id>
    <nct_id>NCT01944982</nct_id>
  </id_info>
  <brief_title>Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma</brief_title>
  <acronym>HNJ-NKAES-2012</acronym>
  <official_title>Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety profile of immunotherapy with natural killer cells and activated
      expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell
      lymphoblastic leukaemia and lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety profile (number of AEs per patient)</measure>
    <time_frame>Two months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections</measure>
    <time_frame>During 14 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to hematological recovery (days)</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hematological recovery: neutrophils &gt;500/mm3, lymphocytes &gt;250/mm3 and platelets &gt;50.000/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of hospitalization in each cycle</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective response rate according to cytomorphic and by &quot;minimal residual disease&quot; criteria (cytometry and/or real time PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of isolation</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma</condition>
  <arm_group>
    <arm_group_label>Activated natural killer cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Activated natural killer cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Expanded haploidentical natural killer cells (NKAEs)</intervention_name>
    <arm_group_label>Activated natural killer cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic
             leukemia or T-cell lymphoblastic lymphoma.

          -  Lansky Index &gt; 60%.

          -  Left ventricular ejection fraction &gt; 39%.

          -  Negative HIV serology.

          -  Provide informed consent in accordance with current legislation.

        Exclusion Criteria:

          -  Patients with a history of poor compliance.

          -  Patients not valid after psycho-social evaluation

          -  Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI
             CTCAE v3 criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pérez-Martínez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service of Pediatric Hematology-Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Pérez-Martínez, MD, PhD</last_name>
    <phone>+34917277223</phone>
    <email>aperezmartinez@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Hematology-Oncology; Hospital Infantil Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pérez-Martínez, MD</last_name>
      <phone>+34917277223</phone>
      <email>aperezmartinez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Antonio Pérez Martínez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 3, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Antonio Perez-Martinez</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>NKAEs</keyword>
  <keyword>Expanded haploidentical natural killer cells</keyword>
  <keyword>Activated natural killer cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
